The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.

A heteroaromatic amide derivative or salt thereof showing high efficacy for diseases associated with Nav1.7 is represented by general formula (I)

##STR00001## [wherein, X.sup.1-X.sup.2 is N—C or C—N, Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are —CH.sub.2—, —CR.sup.4aH— or —O— and so on, Z.sup.1 is —O— and so on, ring A is a 3- to 7-membered monocyclic aromatic ring and so on, R.sup.1a and R.sup.1b are a hydrogen atom or a halogen atom and so on, R.sup.2 is a hydrogen atom and so on, R.sup.3a, R.sup.3b and R.sup.3c are a hydrogen atom or an optionally substituted C.sub.1-C.sub.6 haloalkyl group and so on, R.sup.4a, R.sup.4b and R.sup.4c are, an optionally substituted C.sub.1-C.sub.6 haloalkyl group or C.sub.1-C.sub.6 haloalkoxy group and so on, R.sup.5a is a hydrogen atom and so on, R.sup.5a and R.sup.5b together form —CH.sub.2O— and so on, R.sup.6a and R.sup.6b are a hydrogen atom and so on, n is 1 or 2.].

Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R.sup.1 represents a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.2 and R.sup.3 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.4 and R.sup.5 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.6 represents a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.7 and R.sup.8 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.9 and R.sup.10 are the same as or different from each other, and represent a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; R.sup.11 represents a hydrogen atom, a C.sub.1-6 alkyl group which may have a substituent, etc.; A and B differently represent a methyl group, a carbonyl group, etc.; and X represents a nitrogen atom or an N-oxide.).

Methods for treating conditions including itch and pain are described. The methods include administering a therapeutically effective amount of an N-substituted indole Nav1.7 inhibitor to a subject in need thereof. New N-substituted indole compounds, useful as Nav1.7 inhibitors for the treatment of itch and/or pain are also provided, as well as pharmaceutical compositions containing the Nav1.7 inhibitors.

Methods for treating conditions including itch and pain are described. The methods include administering a therapeutically effective amount of an N-substituted indole Nav1.7 inhibitor to a subject in need thereof. New N-substituted indole compounds, useful as Nav1.7 inhibitors for the treatment of itch and/or pain are also provided, as well as pharmaceutical compositions containing the Nav1.7 inhibitors.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V.sub.H, V.sub.L, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.